What is the required dilution volume and delivery rate for Tecentriq (atezolizumab) 1200mg/20mL and Avastin (bevacizumab) 1200mg/48mL for the 4th cycle?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

There are no official guidelines to assist in answering this question. I will search for relevant research papers instead.

From the FDA Drug Label

DOSAGE AND ADMINISTRATION Administer TECENTRIQ intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.

When administering with chemotherapy with or without bevacizumab, administer TECENTRIQ prior to chemotherapy and bevacizumab when given on the same day.

Bevacizumab is administered at 15 mg/kg every 3 weeks.

The required dilution volume is not specified in the label for Tecentriq (atezolizumab) 1200mg/20mL or Avastin (bevacizumab) 1200mg/48mL. The delivery rate for Tecentriq is over 60 minutes for the first infusion and may be delivered over 30 minutes for subsequent infusions. The delivery rate for Avastin is not specified in the label. For the 4th cycle, the same delivery rates apply as the label does not specify changes in delivery rates based on the cycle number 1.

From the Research

Required Dilution Volume and Delivery Rate

The required dilution volume and delivery rate for Tecentriq (atezolizumab) 1200mg/20mL and Avastin (bevacizumab) 1200mg/48mL for the 4th cycle are not explicitly stated in the provided studies. However, the studies provide information on the dosing and administration of these drugs in various clinical trials.

Dosing and Administration

  • Atezolizumab is administered at a dose of 1200 mg every 3 weeks 2, 3, 4, 5.
  • Bevacizumab is administered at a dose of 15 mg/kg every 3 weeks 2, 3, 4 or 7.5 mg/kg every 3 weeks 5.
  • The studies do not provide information on the required dilution volume and delivery rate for these drugs.

Key Points

  • The studies provide information on the efficacy and safety of atezolizumab and bevacizumab in various clinical trials, but do not provide specific guidance on the required dilution volume and delivery rate.
  • The dosing and administration of these drugs may vary depending on the specific clinical trial or treatment regimen.
  • It is essential to consult the prescribing information and clinical guidelines for specific guidance on the administration of these drugs.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.